Preview

Нервно-мышечные болезни

Расширенный поиск

Боковой амиотрофический склероз: механизмы патогенеза и новые подходы к фармакотерапии (обзор литературы)


https://doi.org/10.17650/2222-8721-2018-8-4-12-18

Полный текст:

Аннотация

Боковой амиотрофический склероз – тяжелое нейродегенеративное заболевание, обусловленное поражением двигательных нейронов головного и спинного мозга и приводящее к тяжелой инвалидизации и смерти через 3–5 лет с момента его дебюта. В последние 2 десятилетия достигнут значительный прогресс в изучении патогенетических механизмов развития данного заболевания. Рилузол и эдаравон, одобренные Управлением по контролю за качеством пищевых продуктов и лекарственных препаратов (Food and Drug Administration) в 2003 и 2017 гг. для лечения бокового амиотрофического склероза, оказались недостаточно эффективны, поэтому продолжается поиск новых препаратов. В статье обсуждаются современные достижения и некоторые перспективные направления патогенетической терапии бокового амиотрофического склероза.

Об авторах

Т. М. Алексеева
ФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России
Россия
197341 Санкт-Петербург, ул. Аккуратова, 2


Т. Р. Стучевская
СПб ГБУЗ «Городская многопрофильная больница № 2»
Россия
194354 Санкт-Петербург, Учебный пер., 5


В. С. Демешонок
ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России
Россия

Вера Сергеевна Демешонок 

 

195067 Санкт-Петербург, просп. Пискаревский, 47



Список литературы

1. Logroscino G., Traynor B.J., Hardiman O. et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010;81(4):385–90. DOI: 10.1136/jnnp.2009.183525. PMID: 19710046.

2. Marin B., Boumédiene F., Logroscino G. et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol 2017;46(1): 57–74. DOI: 10.1093/ije/dyw061. PMID: 27185810.

3. Chio A.G., Logroscino G., Traynor B.J. et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 2013;41(2):118–30. DOI: 10.1159/000351153. PMID: 23860588.

4. Lacomblez L., Bensimon G., Leigh P.N. et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Аmyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347(9013):1425–31. DOI: 10.5555/uri:pii:S0140673696916803. PMID: 8676624.

5. Riviere M., Meininger V., Zeisser P., Munsat T. An analysis of extended survival in patients with ALS treated with riluzole. Arch Neurol 1998;55(4):526–8. DOI: 10.1001/archneur.55.4.526. PMID: 9561981.

6. Brooks B.R., Belden D.S., Roelke K. et al. Survival in non-riluzole treated amyotrophic lateral sclerosis (ALS) – motor neuron disease (MND) patients with disease onset before and since 1996 is identical: a clinic-based epidemiological study. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2(Suppl 2):60–1.

7. Turner M.R., Bakker M., Sham P. et al. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3(1):15–21. DOI: 10.1080/146608202317576499. PMID: 12061944.

8. Al-Chalabi A., Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013;9(11):617–28. DOI: 10.1038/nrneurol.2013.203. PMID: 24126629.

9. Васенина Е.Е., Левин О.С. Окислительный стресс в патогенезе нейродегенеративных заболеваний: возможности терапии. Современная терапия в психиатрии и неврологии 2013;3(4): 39–46.

10. King A.E., Woodhouse A., Kirkcaldie M.T., Vickers J.C. Excitotoxicity in ALS: Overstimulation, or overreaction? Exp Neurol 2016;275:162–71. DOI: 10.1016/j.expneurol.2015.09.019. PMID: 26584004.

11. Bräuer S., Zimyanin V., Hermann A. Prion-like properties of disease-relevant proteins in amyotrophic lateral sclerosis. J Neural Transm (Vienna) 2018;125(4):591–613. DOI: 10.1007/s00702-018-1851-y. PMID: 29417336.

12. Ramesh N., Pandey U.B. Autophagy dysregulation in ALS: When protein aggregates get out of hand. Front Mol Neurosci 2017;10:263. DOI: 10.3389/fn-mol.2017.00263. PMID: 28878620.

13. Hooten K.G., Beers D.R., Zhao W., Appel S.H. Protective and toxic neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics 2015;12(2):364–75. DOI: 10.1007/s13311-014-0329-3. PMID: 25567201.

14. Ugras S.E., Shorter J. RNA-binding proteins in amyotrophic lateral sclerosis and neurodegeneration. Neurol Res Int 2012;2012:432780. DOI: 10.1155/2012/432780. PMID: 22919483.

15. De Vos K.J., Hafezparast M. Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research? Neurobiol Dis 2017;105:283–99. DOI: 1016/j. nbd.2017.02.004. PMID: 28235672.

16. Smith E.F., Shaw P.J., De Vos K.J. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett 2017 Jun 30. Available at: https://www.sciencedirect.com/science/article/pii/S030439401730544X?via%3Dihub. DOI: 10.1016/j.neulet.2017.06.052. PMID: 28669745.

17. Al-Chalabi A., Calvo A., Chio A. et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol 2014;13(11):1108–13. DOI: 10.1016/S1474-4422(14)70219-4. PMID: 25300936.

18. Chia R., Chiò A., Traynor B.J. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol 2018;17(1):94–102. DOI: 10.1016/S1474-4422(17)30401-5. PMID: 29154141.

19. Maurel C., Dangoumau A., Marouillat S. Causative genes in amyotrophic lateral sclerosis and protein degradation pathways: a link to neurodegeneration. Mol Neurobiol 2018;55(8);6480–99. DOI: 10.1007/s12035-017-0856-0. PMID: 29322304.

20. Blokhuis A.M., Groen E.J., Koppers M. et al. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol 2013;125(6):777–94. DOI: 10.1007/s00401-013-1125-6. PMID: 23673820.

21. Liu J., Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol 2017;8:1005. DOI: 10.3389/fimmu.2017.01005. PMID: 28871262.

22. Markiewicz I., Lukomska B. The role of astrocytes in the physiology and pathology of the central nervous system. Acta Neurobiol Exp 2006;66(4):343–58. PMID:17265695

23. Talbot K., Turner M.R., Mersden R. et al. Motor neuron disease. A practical manual. New York: Oxford University Press, 2009. 214 p. DOI: 10.1093/ med/9780199547364.003.02.

24. Мамчур В.И., Кравченко К.А., Опрышко В.И. Нейрофармакологический профиль действия глутаматергических препаратов (обзор литературы и собственных исследований). Журнал Академии медицинских наук Украины 2009;15(1):50–69.

25. Miyaji Y., Yoshimura S., Sakai N. et al. Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion: subanalysis of RESCUE-Japan registry. Neurol Med Chir (Tokyo) 2015;55(3):241–7. DOI: 2176/nmc.ra.20140219. PMID: 25739433.

26. Brooks B.R., Miller R.G., Swash M. et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1(5):293–9. DOI: 10.1080/146608200300079536. PMID: 11464847.

27. Abe K., Aoki M., Tsuji S. et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16(7):505–12. DOI: 10.1016/S14744422(17)30115-1. PMID: 28522181.

28. Mora J.S., Hermine O. Masitinib as an add-on therapy to riluzole is safe and effective in the treatment of amyotrophic lateral sclerosis (ALS). J Neurol Sci 2017;381(10):183. DOI: 10.1016/j.jns.2017.08.526

29. Miller R.G., Block G., Katz J. S. et al. Randomized phase 2 trial of NP001 – a novel immune regulator: safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm 2015;2(3):100. DOI: 10.1212/NXI.0000000000000100. PMID: 25884010.

30. Lunetta C., Lizio A., Maestri E. Serum C-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis. JAMA Neurol 2017;74(6):660–7. DOI: 10.1001/jamaneurol.2016.6179. PMID: 28384752.

31. Mizuno T., Kurotani T., Komatsu Y. et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology 2004;46(3):404–11. DOI: 10.1016/j.neuropharm.2003.09.009. PMID: 14975696.

32. Brooks B.R., Bravver E., Sanjak M. et al. Adaptive design single center phosphodiesterase type 4 (PDE4) inhibitor – ibudilast (MN-166-ALS-1201) phase 1b/2a clinical trial double-blind (DB) with open label extension (OLE) [NCT02238626] for amyotrophic lateral sclerosis (ALS) patients [1] not requiring non-invasive ventilation (no NIV) up to 5 years (Early Cohort – EC) and [2] requiring non-invasive ventilation (NIV) up to 10 years (advanced NIV cohort – ANC) from disease onset – report of clinical trial DB, OLE and post-treatment cessation epochs – perprotocol (PP) treatment completion associated with improved survival and post treatment cessation loss of muscle strength (P3.127). Neurology 2017;88(16).

33. Ascherio A., LeWitt P.A., Xu K. et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009;66(12):1460–8. DOI: 10.1001/archneurol.2009.247. PMID: 19822770.

34. Schwarzschild M.A., Ascherio A., Beal M.F. et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol 2014;71(2):141–50. DOI: 10.1001/jamaneurol.2013.5528. PMID: 24366103.

35. Paganoni S., Zhang M., Quiroz Zárate A. et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol 2012;259(9):1923–8. DOI: 10.1007/s00415-012-6440-7. PMID: 22323210.

36. Atassi N., Berry J., Shui A. et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology 2014;83(19):1719–25. DOI: 10.1212/WNL.0000000000000951. PMID: 25298304.

37. Elia A.E., Lalli S., Monsurrò M.R. et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol 2016;23(1):45-52. PMID: 25664595. DOI: 10.1111/ene.12664.

38. Patten S.A., Aggad D., Martinez. J. et al. Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis. JCI Insight 2017;2(22):e97152. DOI: 10.1172/jci.insight.97152. PMID: 29202456.

39. Cudkowicz M.E., Shefner J.M., Simpson E. et al. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. MuscleNerve 2008;38(1):837-44. DOI: 10.1002/mus.21059. PMID: 18551622.

40. Barral J.M., Broadley S.A., Schaffar G., Hartl F.U. Roles of molecular chaperones in protein misfolding diseases. Semin Cell Dev Biol 2004;15(1):17–29. DOI: 10.1016/j.semcdb.2003.12.010. PMID: 15036203.

41. Kieran D., Kalmar B., Dick J.R. et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004;10(4):402-5. DOI: 10.1038/nm1021. PMID: 15034571.

42. Benatar M.M., Wuu J., Andersen P.M. et al. Randomized, double-blind, placebocontrolled trial of arimoclomol in rapidly progressive SOD1 ALS Neurology 2018;90(7):565-74. DOI: 10.1212/WNL.0000000000004960. PMID: 29367439.

43. Garnock-Jones K.P. Dextromethorphan/ quinidine: in pseudobulbar affect. CNS Drugs 2011;25(5):435-45. DOI: 10.2165/11207260-000000000-00000. PMID: 21476614.

44. Pioro E.P., Brooks B.R., Cummings J. et al. Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol 2010;68(5):693-702. DOI: 10.1002/ana.22093. PMID: 20839238.

45. Smith R., Pioro E., Myers K. et al. Enhanced bulbar function in amyotrophic lateral sclerosis: the nuedexta treatment trial. Neurotherapeutics 2017;14(3):762-72. DOI: 10.1007/s13311-016-0508-5. PMID: 28070747.

46. Trias E., Ibarburu S., Barreto-Núñez R. et al. Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS. JCI Insight 2017;2(20):e95934. DOI: 10.1172/jci.insight.95934. PMID: 29046475.

47. RocheJ.C., Rojas-Garcia R., Scott K. M. et al. A proposed staging system for amyotrophic lateral sclerosis. Brain 2012;135(3):847–52. DOI: 10.1093/brain/awr351. PMID: 22271664.


Для цитирования:


Алексеева Т.М., Стучевская Т.Р., Демешонок В.С. Боковой амиотрофический склероз: механизмы патогенеза и новые подходы к фармакотерапии (обзор литературы). Нервно-мышечные болезни. 2018;8(4):12-18. https://doi.org/10.17650/2222-8721-2018-8-4-12-18

For citation:


Alekseeva T.M., Stuchevskaya T.R., Demeshonok V.S. Amyotrophic lateral sclerosis: pathogenetic mechanisms and new approaches to pharmacotherapy (literature review). Neuromuscular Diseases. 2018;8(4):12-18. (In Russ.) https://doi.org/10.17650/2222-8721-2018-8-4-12-18

Просмотров: 28


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2222-8721 (Print)
ISSN 2413-0443 (Online)